Press Release
Terumo Announces Change of Executive Officers
TOKYO, JAPAN - February 9, 2023 - Terumo Corporation (TSE: 4543) hereby announces that it has resolved a change of its Executive Officers as follows.
1. Change of Director (As of April 1, 2023)
Name | New position | Current position | |||
Director and Group Managing | |||||
Executive Officer | |||||
Chief Human Resources Officer | |||||
Kyo Nishikawa | Director and Corporate Advisor | (CHRO) | |||
Human Resources Division | |||||
IT Planning Dept. | |||||
Asia Pacific Region and India | |||||
Terumo Medical Pranex | |||||
2. New Candidate for Director (As of June 27, 2023)
(It is subject to the approval at the Annual General Meeting of Shareholders to be held on the same day)
Name | New position | Current position as of April 1, 2023 | |||||
Directorand Group Managing | Group Managing Executive Officer | ||||||
Executive Officer | |||||||
Norimasa | Corporate Value Promotion Division | ||||||
Corporate Value Promotion Division | |||||||
Kunimoto | Human Resources Division | ||||||
Human Resources Division | |||||||
Japan Sales Dept. | |||||||
Japan Sales Dept. | |||||||
3. Change of Group Executive Officer and Executive Officer (As of April 1, 2023) | |||||||
Name | New position | Current position | |||||
Group Managing Executive Officer: GMEO | |||||||
Director and Group Senior Managing | Director and Group Senior Managing | ||||||
Executive Officer | Executive Officer | ||||||
Corporate Affairs Dept. | |||||||
Corporate Affairs Dept. | |||||||
Shoji Hatano | Legal and Compliance Division | ||||||
Legal and Compliance Dept. | |||||||
IT Planning Dept. | |||||||
Corporate Value Promotion Division | |||||||
Intellectual Property Dept. | |||||||
Japan Sales Division | |||||||
Terumo Medical Pranex | |||||||
Terumo Call Center | |||||||
Group Managing Executive Officer | Group Executive Officer | ||||||
Regional Representative, Europe, | |||||||
Norimasa | Corporate Value Promotion Division | ||||||
Middle East and Africa | |||||||
Human Resources Division | |||||||
Kunimoto | President and CEO, Terumo Europe | ||||||
Japan Sales Dept. | |||||||
N.V. | |||||||
Group Executive Officer: GEO | |||||||
Group Executive Officer | |||||||
Regional Representative, Europe, | Deputy General Manager, Human | ||||||
Takuya Hosogai | Middle East and Africa | ||||||
Resources Dept. | |||||||
President and CEO, Terumo Europe | |||||||
N.V. | |||||||
Group Executive Officer | |||||||
Katsuyuki Honda | Regional Representative, Americas | Leader, C&V Digital, Cardiac and | |||||
President and CEO, Terumo Americas | Vascular Company | ||||||
Holding, Inc. | |||||||
Group Executive Officer | |||||||
Chief Human Resources Officer | |||||||
(CHRO) | |||||||
General Manager, Global Human | General Manager, Global Human | ||||||
Tomoko Adachi | Resources Dept. | ||||||
Resources Dept. | |||||||
DE&I Promotion Dept. | |||||||
Human Resources Dept. | |||||||
Human Resources Development | |||||||
Dept. | |||||||
Executive Officer: EO | |||||||
Executive Officer | |||||||
Chief Legal Officer (CLO) | Executive Officer | ||||||
Miho Mizuguchi | General Manager, CLO Office | Chief Legal Officer (CLO) | |||||
General Manager, Legal Dept. | General Manager, Legal and | ||||||
Compliance Dept. | Compliance Dept. | ||||||
Promotional Activities Control Dept. |
Executive Officer | Vice President, Hospital Care | |
President,Hospital Care Solution | ||
Toshiyuki Akaike | Solution Division, Medical Care | |
Division, Medical Care Solutions | ||
Solutions Company | ||
Company | ||
About Terumo
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Terumo Corporation published this content on 09 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 February 2023 06:32:07 UTC.